Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief emeritus JCO GO, Board Member @UICC - chair #ATOMcoalition
Miami, FL
- Tweets 59,207
- Following 40,087
- Followers 37,613
- Likes 84,165
Pinned Tweet
My take on Galleri @WSJ @WSJopinion
“People differ in how they value earlier detection, uncertainty, diagnostic risk and out-of-pocket cost. Once regulators have judged the evidence sufficient for access, informed patients and their physicians should be able to examine these results and decide together. Approval need not mean universal screening. It should mean that government doesn’t substitute one national judgment for millions of individual decisions.”
@SylvesterCancer @asco @myESMO
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #WCLC26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgen
wsj.com/opinion/the-galleri-…
7
15
45
6,163
gilberto lopes retweeted
Viel Erfolg tomorrow!!! 🙏 Perioperative chemoimmunotherapy vs preoperative alone is one of the most relevant questions in early-stage NSCLC right now. Bin sehr gespannt auf das Duell! 🥊 #OLNGreatDebates
1
2
55
gilberto lopes retweeted
What the NHS-Galleri Trial Really Tells Us About Multicancer Screening - GILBERTO de lima LOPES Junior
@GlopesMd
oncodaily.com/voices/gilbert…
134
gilberto lopes retweeted
And something we need to learn from in other areas of medicine…
@OpenMedInsights @GlopesMd @DrShubhamPant @allisonoconn @drallysonocean
1
2
48
gilberto lopes retweeted
Absolutely perfectly stated !!! 👇👇👇
No!! The cure definition is aspirational. Stopping maintenance for any patient is a decision that’s made based on the patient’s unique clinical situation, myeloma risk features, the treatment administered, duration and depth of MRD negativity, data on duration of maintenance by drug that we have available etc. Not a decision to be taken lightly.
1
2
4
305
gilberto lopes retweeted
#ISLB2026 If you are working in liquid biopsy or you just want to learn about how it is evolving into so many standards of care, come join us in Madrid. Unique multidisciplinary stakeholder workshop is a highlight. Nothing like it in the world. @isliquidbiopsy @UmbertoMalapel1
🩸🧬Liquid biopsy is reshaping how we think about cancer biology, monitoring and precision treatment. Looking forward to ISLB 2026 in Madrid and the conversations ahead.
@isliquidbiopsy @UmbertoMalapel1 @ChristianRolfo @ElJanLe @drgandara
2
4
7
643
gilberto lopes retweeted
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.
1
12
35
2,460
gilberto lopes retweeted
Completely agree, Luis. Relapsed SCLC patients don’t have 2–3 years to wait. The signal is too strong — hope regulators find a faster path.
1
1
132
gilberto lopes retweeted
Major update for our SMASHERS ⬇️
Today, our @SclcSMASHERS received unfortunate news regarding infintamab deruxtecan (I-DXd).
As you may recall, I-DXd is a B7-H3 directed antibody-drug conjugate (i.e., chemotherapy as a biological Trojan horse) that has been studied in SCLC.
We have been anticipating the @FDA would complete their PDUFA process for accelerated approval of I-DXd by October 2026.
Unfortunately, the company Merck (along with the Rx developer Daichii Sankyo) has WITHDRAWN their application from the FDA for accelerated approval today.
The company expressed concerns that I-DXd may have not been approved with only Phase 2 study findings (IDEATE-LUNG-01, which were positive with high # of responses with brisk time to response) and the Phase 3 study (IDEATE-LUNG-02) is nearing completion.
While I am hopeful that the Phase 3 data for I-DXd in the future, given two positive Phase 3 studies (Tam-Peli and Riz-Rez) at #WCLC26, this update makes it especially challenging, with lurbinectedin being revoked as well for patients who need options for relapsed SCLC, post tarlatamab.
🚨 I cannot emphasize enough that more clinical trials & agents in the space are vital, CLEAR unmet needs exist, and trials should be discussed with our patients at every major treatment decision in #SCLC to improve the care for every patient impacted by SCLC.
@LUNGevity @lungoncdoc @StephenVLiu @alissajcooper @Sonampuri @BZhangMD @LaurenByersMD @BalazsHalmosMD @OncBrothers @OncoAlert @OncLive @YoungLungCancer @Lung_Cancers @RManochakian @Latinamd @TheShieldsLab @lcrf_org @LungCancerEu @oncodaily #lcsm
1
3
681
On #WorldLungDay, we’re highlighting the importance of trusted information for everyone affected by #lungcancer. 🫁
From diagnosis and treatment to advocacy and support, explore IASLC resources for patients and caregivers: iaslc.org/patients-caregiver…
4
13
661
gilberto lopes retweeted
Disappointing news indeed for our patients who need a strong option after tarlatamab, especially given the uncertain status of lurbinectedin approval following its recent withdrawal in the 2nd-line-and-beyond setting.
Clinical trials remain essential. Hopeful we'll see an efficacious and safe ADC approved soon.
@SclcSMASHERS @drshieldsmd @BZhangMD @alissajcooper
Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…
2
3
21
1,514
gilberto lopes retweeted
That’s a wrap on this year’s @theNCI NCORP Meeting! Leaving inspired by our shared mission to bring lifesaving clinical trials to the communities where most cancer care is delivered. Proud to represent @NRGOncology & grateful to work alongside these incredible women.
1
6
316
gilberto lopes retweeted
Team LUNGevity is headed to Berlin this weekend for the BMW Berlin Marathon!
Send your good vibes to our 12 amazing athletes who are running in Germany to raise lung cancer awareness and critical funds for research and support services. Check out teamlungevity.org for more
3
7
447
gilberto lopes retweeted
Small Molecule Drug of the Day- #belzutifan (a hypoxia-inducible factor 2 alpha inhibitor). Happy Friday! Chalkboard Chemistry is fun
Small Molecule Drug of the Day- #belzutifan (a hypoxia-inducible factor 2 alpha inhibitor) interesting scaffold (Inden-4-yl), a bicyclic core with a ether link to Fluorobenzonitrile ring (electrophilic!) Nitrile-containing pharmaceuticals 🧵
pmc.ncbi.nlm.nih.gov/article…
2
7
492
gilberto lopes retweeted
Today, our @SclcSMASHERS received unfortunate news regarding infintamab deruxtecan (I-DXd).
As you may recall, I-DXd is a B7-H3 directed antibody-drug conjugate (i.e., chemotherapy as a biological Trojan horse) that has been studied in SCLC.
We have been anticipating the @FDA would complete their PDUFA process for accelerated approval of I-DXd by October 2026.
Unfortunately, the company Merck (along with the Rx developer Daichii Sankyo) has WITHDRAWN their application from the FDA for accelerated approval today.
The company expressed concerns that I-DXd may have not been approved with only Phase 2 study findings (IDEATE-LUNG-01, which were positive with high # of responses with brisk time to response) and the Phase 3 study (IDEATE-LUNG-02) is nearing completion.
While I am hopeful that the Phase 3 data for I-DXd in the future, given two positive Phase 3 studies (Tam-Peli and Riz-Rez) at #WCLC26, this update makes it especially challenging, with lurbinectedin being revoked as well for patients who need options for relapsed SCLC, post tarlatamab.
🚨 I cannot emphasize enough that more clinical trials & agents in the space are vital, CLEAR unmet needs exist, and trials should be discussed with our patients at every major treatment decision in #SCLC to improve the care for every patient impacted by SCLC.
@LUNGevity @lungoncdoc @StephenVLiu @alissajcooper @Sonampuri @BZhangMD @LaurenByersMD @BalazsHalmosMD @OncBrothers @OncoAlert @OncLive @YoungLungCancer @Lung_Cancers @RManochakian @Latinamd @TheShieldsLab @lcrf_org @LungCancerEu @oncodaily #lcsm
2
18
48
4,475
gilberto lopes retweeted
Precision without access is just privilege.
This new @TheLancetOncol Commission turns that concern into a global roadmap for equitable cancer genomics and precision oncology. Congratulations to all involved.
@OncoAlert @OpenMedicineHQ @isliquidbiopsy @myESMO @ASCO @VivekSubbiah @Dr_R_Kurzrock
2
8
20
933
gilberto lopes retweeted
International Association for the Study of Lung Cancer - LALCA 2026 Connects Lung Cancer Experts Across Latin America
@IASLC
1
2
4
138
gilberto lopes retweeted
More than 2,000 people from across the global cancer community are convening in Hong Kong.
That may be the most important function of a congress like this: bringing people together across countries, disciplines and lived experience so that ideas can become action.
1
1
1
151
gilberto lopes retweeted
Read our perspective @OncUpdates on the 7-year CROWN data and what the remarkable durability of systemic and intracranial disease control with lorlatinib means for the evolving first-line treatment landscape in ALK+ NSCLC.
🫁🧠
#LungCancer #NSCLC #ALK #PrecisionOncology #lcsm
@SylvesterCancer @OncBrothers @Latinamd @GlopesMd @HemOncMiami
⭐️ #CROWN at 7 yrs: new benchmark for 1L #ALK+ #NSCLC
🫁Lorlatinib vs crizotinib
✅7-yr PFS 55% vs 3%
🧠No new intracranial progression after 30 mo (~92% IC-free at 7 yrs)
@diya_jayram @Jani_Chinmay @HemOncMiami @GlopesMd
#lcsm #LungCancer #OncTwitter
oncupdates.com/article/crown…
3
9
714